Top

Published in:

01-04-2000 | Commentary

Founder populations and their uses for breast cancer genetics

Author: Susan L Neuhausen

Published in: Breast Cancer Research | Issue 2/2000

Abstract

Numerous founder mutations have been reported in BRCA1 and BRCA2. For genetic screening of a population with a founder mutation, testing can be targeted to the mutation, allowing for a more rapid and less expensive test. In addition, more precise estimates of the prior probability of carrying a mutation and of the likelihood of a mutation carrier developing cancer should be possible. For a given founder mutation a large number of carriers are available, so that focused scientific studies of penetrance, expression, and genetic and environmental modifiers of risk can be performed. Finally, founder populations may be a powerful resource to localize additional breast cancer susceptibility loci, because of the reduction in locus heterogeneity.

Kaback M, Lim-Steele J, Dabholkar D, et al: Tay-Sachs disease: carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. The International TSD Data Collection Network. JAMA. 1993, 270: 2307-2315. 10.1001/jama.270.19.2307.CrossRefPubMed

de la Chapelle A: Disease gene mapping in isolated human populations: the example of Finland. J Med Genet. 1993, 30: 857-865.CrossRefPubMedPubMedCentral

Diamond JM, Rotter JI: Observing the founder effect in human evolution [news]. Nature. 1987, 329: 105-106. 10.1038/329105a0.CrossRefPubMed

Puffenberger EG, Kauffman ER, Bolk S, et al: Identity-by-descent and association mapping of a recessive gene for Hirschsprung disease on human chromosome 13q22. Hum Mol Genet. 1994, 3: 1217-1225.CrossRefPubMed

Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994, 266: 66-71.CrossRefPubMed

Wooster R, Bignell G, Lancaster J, et al: Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995, 378: 789-792. 10.1038/378789a0.CrossRefPubMed

Shen D, Vadgama JV: BRCA1 and BRCA2 gene mutation analysis: visit to the Breast Cancer Information Core (BIC). Oncol Res. 1999, 11: 63-69.PubMed

Breast Cancer Information Core Database:. [http://www.nhgri.nih.gov/Intramural-research/Lab-transfer/Bic/]

Neuhausen SL, Mazoyer S, Friedman L, et al: Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet. 1996, 58: 271-280.PubMedPubMedCentral

10.

Neuhausen SL, Godwin AK, Gershoni-Baruch R, et al: Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet. 1998, 62: 1381-1388. 10.1086/301885.CrossRefPubMedPubMedCentral

11.

Claus EB, Schildkraut JM, Thompson WD, Risch NJ: The genetic attributable risk of breast and ovarian cancer. Cancer. 1996, 77: 2318-2324. 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z.CrossRefPubMed

12.

Peto J, Collins N, Barfoot R, et al: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999, 91: 943-949. 10.1093/jnci/91.11.943.CrossRefPubMed

13.

Couch FJ, DeShano ML, Blackwood MA, et al: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997, 336: 1409-1415. 10.1056/NEJM199705153362002.CrossRefPubMed

14.

Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E: Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997, 89: 227-238. 10.1093/jnci/89.3.227.CrossRefPubMed

15.

Frank TS, Manley SA, Olopade OI, et al: Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998, 16: 2417-2425.PubMed

16.

Schmidt S, Becher H, Chang-Claude J: Breast cancer risk assessment: use of complete pedigree information and the effect of mis-specified ages at diagnosis of affected relatives. Hum Genet. 1998, 102: 348-356. 10.1007/s004390050704.CrossRefPubMed

17.

Petrij-Bosch A, Peelen T, van Vliet M, et al: BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nature Genet. 1997, 17: 341-345.CrossRefPubMed

18.

Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997, 336: 1401-1408. 10.1056/NEJM199705153362001.CrossRefPubMed

19.

Hopper JL, Southey MC, Dite GS, et al: Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev. 1999, 8: 741-747.PubMed

20.

Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998, 62: 676-689. 10.1086/301749.CrossRefPubMedPubMedCentral

21.

Gayther SA, Warren W, Mazoyer S, et al: Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nature Genet. 1995, 11: 428-433.CrossRefPubMed

22.

Gayther SA, Mangion J, Russell P, et al: Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nature Genet. 1997, 15: 103-105.CrossRefPubMed

23.

Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst. 1999, 91: 1310-1316. 10.1093/jnci/91.15.1310.

24.

Thorlacius S, Sigurdsson S, Bjarnadottir H, et al: Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997, 60: 1079-1084.PubMedPubMedCentral

25.

Claus EB, Risch N, Thompson WD: Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991, 48: 232-242.PubMedPubMedCentral

26.

Vehmanen P, Friedman LS, Eerola H, et al: A low proportion of BRCA2 mutations in Finnish breast cancer families. Am J Hum Genet. 1997, 60: 1050-1058.PubMedPubMedCentral

27.

Huusko P, Paakkonen K, Launonen V, et al: Evidence of founder mutations in Finnish BRCA1 and BRCA2 families [letter]. Am J Hum Genet. 1998, 62: 1544-1548. 10.1086/301880.CrossRefPubMedPubMedCentral

28.

Thorlacius S, Olafsdottir G, Tryggvadottir L, et al: A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nature Genet. 1996, 13: 117-119.CrossRefPubMed

29.

Sigurdsson S, Thorlacius S, Tomasson J, et al: BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med. 1997, 75: 758-761. 10.1007/s001090050162.CrossRefPubMed

30.

Thorlacius S, Struewing JP, Hartge P, et al: Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet. 1998, 352: 1337-1339. 10.1016/S0140-6736(98)03300-5.CrossRefPubMed

31.

Neuhausen S, Gilewski T, Norton L, et al: Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genet. 1996, 13: 126-128.CrossRefPubMed

32.

Roa BB, Boyd AA, Volcik K, Richards CS: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genet. 1996, 14: 185-187.CrossRefPubMed

33.

Oddoux C, Struewing JP, Clayton CM, et al: The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nature Genet. 1996, 14: 188-190.CrossRefPubMed

34.

Struewing JP, Abeliovich D, Peretz T, et al: The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature Genet. 1995, 11: 198-200.CrossRefPubMed

35.

Levy-Lahad E, Catane R, Eisenberg S, et al: Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet. 1997, 60: 1059-1067.PubMedPubMedCentral

36.

Abeliovich D, Kaduri L, Lerer I, et al: The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet. 1997, 60: 505-514.PubMedPubMedCentral

37.

Friedman LS, Szabo CI, Ostermeyer EA, et al: Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet. 1995, 57: 1284-1297.PubMedPubMedCentral

38.

Tonin P, Serova O, Lenoir G, et al: BRCA1 mutations in Ashkenazi Jewish women [letter]. Am J Hum Genet. 1995, 57: 189-PubMedPubMedCentral

39.

Simard J, Tonin P, Durocher F, et al: Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nature Genet. 1994, 8: 392-398.CrossRefPubMed

40.

Mefford HC, Baumbach L, Panguluri RC, et al: Evidence for a BRCA1 founder mutation in families of West African ancestry [letter]. Am J Hum Genet. 1999, 65: 575-578. 10.1086/302511.CrossRefPubMedPubMedCentral

41.

Gao Q, Neuhausen S, Cummings S, Luce M, Olopade OI: Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer [letter]. Am J Hum Genet. 1997, 60: 1233-1236.PubMedPubMedCentral

42.

Claes K, Machackova E, De Vos M, et al: Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation BRCA1 IVS5 + 3A > G. Dis Markers. 1999, 15: 69-73.CrossRefPubMedPubMedCentral

43.

Peelen T, van Vliet M, Petrij-Bosch A, et al: A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet. 1997, 60: 1041-1049.PubMedPubMedCentral

44.

Tonin PM, Mes-Masson AM, Narod SA, Ghadirian P, Provencher D: Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clin Genet. 1999, 55: 318-324. 10.1034/j.1399-0004.1999.550504.x.CrossRefPubMed

45.

Backe J, Hofferbert S, Skawran B, et al: Frequency of BRCA1 mutation 5382insC in German breast cancer patients. Gynecol Oncol. 1999, 72: 402-406. 10.1006/gyno.1998.5270.CrossRefPubMed

46.

Csokay B, Tihomirova L, Stengrevics A, Sinicka O, Olah E: Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia. Mutation in brief no. 258. Online. Hum Mutat. 1999, 14: 92-10.1002/(SICI)1098-1004(1999)14:1<92::AID-HUMU23>3.0.CO;2-2.CrossRefPubMed

47.

Andersen TI, Borresen AL, Moller P: A common BRCA1 mutation in Norwegian breast and ovarian cancer families? [letter]. Am J Hum Genet. 1996, 59: 486-487.PubMedPubMedCentral

48.

Borg A, Dorum A, Heimdal K, et al: BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations. Dis Markers. 1999, 15: 79-84.CrossRefPubMedPubMedCentral

49.

Dorum A, Hovig E, Trope C, Inganas M, Moller P: Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA. Eur J Cancer. 1999, 35: 779-781. 10.1016/S0959-8049(99)00050-7.CrossRefPubMed

50.

Gayther SA, Harrington P, Russell P, et al: Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia [letter]. Am J Hum Genet. 1997, 60: 1239-1242.PubMedPubMedCentral

51.

Johannsson O, Ostermeyer EA, Hakansson S, et al: Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet. 1996, 58: 441-450.PubMedPubMedCentral

Title: Founder populations and their uses for breast cancer genetics
Author: Susan L Neuhausen
Publication date: 01-04-2000
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 2/2000
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr36

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2000

Transforming growth factor-β and breast cancer: Transforming growth factor-β/SMAD signaling defects and cancer

Transforming growth factor-β and breast cancer: Mammary gland development

Transforming growth factor-β and breast cancer: Introduction

Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development

Transforming growth factor-β and breast cancer: Lessons learned from genetically altered mouse models

Caretaker Brca1: keeping the genome in the straight and narrow

Keynote webinar | Spotlight on antibody–drug conjugates in cancer